BiotechTube

LY3875383 + Placebo

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertriglyceridemia

Conditions

Hypertriglyceridemia

Trial Timeline

Nov 14, 2022 → Jan 10, 2024

NCT ID
NCT05609825

About LY3875383 + Placebo

LY3875383 + Placebo is a phase 1 stage product being developed by Eli Lilly for Hypertriglyceridemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT05609825. Target conditions include Hypertriglyceridemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05609825Phase 1Terminated

Competing Products

20 competing products in Hypertriglyceridemia

See all competitors
ProductCompanyStageHype Score
ZYH7 + ZYH7 + ZYH7 + FenofibrateZydus LifesciencesPhase 2
52
Solbinsiran + PlaceboEli LillyPhase 2
52
Placebo + Ethyl IcosapentateSumitomo PharmaPhase 3
77
Omega-3-Acid Ethyl Esters 90 Soft Capsules + Corn OilJiangsu Hengrui MedicinePhase 3
77
warfarin + omefas + omega-3-acid ethyl estersAstraZenecaPhase 1
33
rosuvastatinAstraZenecaApproved
85
Simvastatin + acetylsalicylic acid (ASA) + omefasAstraZenecaPhase 1
33
Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4gAstraZenecaPhase 3
77
Epanova (4 g) and Lovaza (4 g) + Lovaza (4 g) and Epanova (4 g)AstraZenecaPhase 2
52
rosuvastatin 40 mg tablet + Epanova™ QD (2 x 1 g capsules) + Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose + Multiple (20) oral doses of 2 g Vascepa® every 12 hoursAstraZenecaPhase 1
33
placebo + omefas + omefas + omefasAstraZenecaPhase 2/3
65
Epanova + LovazaAstraZenecaPhase 1
33
Epanova + Olive OilAstraZenecaPhase 3
77
AZD0585 + AZD0585 placeboAstraZenecaPhase 3
77
ABT-143 + simvastatinAstraZenecaPhase 3
77
MaravirocPfizerPhase 1
32
torcetrapib/atorvastatin + atorvastatinPfizerPhase 3
76
Icosapent (MND-2119) + Icosapent (EPADEL CAPSULES 300)Mochida PharmaceuticalPhase 3
76
IcosapentMochida PharmaceuticalPhase 3
76
REGN1500 + placeboRegeneron PharmaceuticalsPhase 1
32

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85